|
Divi's Laboratories Limited was established in the year
1990 as a R & D company to develop processes for API’s
& Intermediates and to provide turnkey solutions to the
industry. In 1995, the company's first manufacturing unit
was built on a 300 acre site comprising of 11 multi-purpose
production blocks.
Divi's has taken up development of a new site (Unit-II) in
the year 2002 at Chippada village 35 km from Visakhapatnam
on the east coast of India. The facility has been commissioned
and will commence operations in early 2003.
Divi’s Laboratories is being promoted by Mr. Murali
K. Divi Who co-promoted Cheminor Drugs Ltd for 6 years as
an Managing Director playing an key role in process development
and manufacture of Ibuprofen, NMSM and Ranitidine.
Divi’s has a ready pipeline of intermediates for various
new products which are in different phases of development.
The table below indicates the number of molecules under discovery.
| Stage |
Nos. of Molecules |
| Phase I - Animal Studies |
20 |
| Phase II - Human Studies (Sample) |
21 |
| Phase III - Human Studies (Population) |
17 |
| Already Launched |
25 |
| Peptides |
12 |
Divi's also undertakes FTE/Contract Research on process development
for discovery compounds of leading MNCs the world over and
is a major supplier of APIs for the MNCs. Since the commencement
of production in 1995, about 90 % of the company's turnover
comes from exports.
Divi’s Laboratories are primarily engaged in the manufacture
of APIs & intermediates for generics, advanced intermediates
for discovery compounds, custom synthesis for pharma giants.
Divi’s is also active in building blocks for Peptides,
Nucleotides and Carotenoids Divi’s enjoys US FDA certification
for Naproxen, Naproxen Sodium, Diltiazem, and Dextromethorphan.
Divi's also enjoys a cGMP inspection for the company's manufacturing
facilities.
Divi's strives to be a leading player in contract research
and customs synthesis business for APIs and intermediates
and plays a complimentary role to MNC innovator pharma giants.
Divi’s would continue to focus on generics products,
due to integrated nature of its manufacturing facilities.
Divi has taken a strategic decision to adhering to IPR to
migrate to IPR compliance from January 2005 onwards.
Divi’s also changed its accounting policy on R&
D expenditure charged off to revenue as against the earlier
practice of writing as Deferred expenditure. |
